Joint academic and industrial efforts towards innovative and efficient solutions for clinical needs

Abstract

The 4 Translational Research Symposium (TRS) was organised at the annual meeting of the European Society for Biomaterials (ESB) 2017, Athens, Greece, with a focus on 'Academia-Industry Clusters of Research for Innovation Catalysis'. Collaborations between research institutes and industry can be sustained in several ways such as: European Union (EU) funded consortiums; syndicates of academic institutes, clinicians and industries; funding from national governments; and private collaborations between universities and companies. Invited speakers from industry and research institutions presented examples of these collaborations in the translation of research ideas or concepts into marketable products. The aim of the present article is to summarize the key messages conveyed during these lectures. In particular, emphasis is put on the challenges to appropriately identify and select unmet clinical needs and their translation by ultimately implementing innovative and efficient solutions achieved through joint academic and industrial efforts.

Prospects of Advanced Therapy Medicinal Products–Based Therapies in Regenerative Dentistry: Current Status, Comparison with Global Trends in Medicine, and Future Perspectives

“…ATMPs represent complex biomedicines containing living cells or subcellular fractions with biological functions, which require highlevel scientific evaluation of their safety and efficacy before proceeding to commercialization, technology adoption, and clinical application 51 . A significant effort has been attempted by stakeholders in the EU and worldwide during the past few years to overcome the "Death Valley" of clinical translation and to develop multilevel implementation plans to accelerate patient accessibility in ATMP-based treatments 12,19 ; their results, however, are yet to be seen.…”

Enabling MedTech Translation in Academia: Redefining Value Proposition with Updated Regulations

“…International and inter-sectoral partnerships are essential for successful clinical translation into a global market. [12] Initiatives such as The European Clinical Research Infrastructure Network (ECRIN), should facilitate multinational clinical research among scientific collaborations and consortia across Europe. ECRIN provides services to support clinical trials and ensure standard operating procedures are consistently implemented, creating reproducible, high-quality data while overcoming resource constraints [13] Although industrial partnerships are vital to driving technological advances towards the market, nongovernmental bodies such as ECRIN fulfill a critical role to ensure clinical research and innovation are scientifically substantiated, transparent, and meet demanding regulatory stipulations.…”

When patient advocacy organizations meet industry: a novel approach to dealing with financial conflicts of interest

“…Academic-industry partnerships have become central to producing advances in biomedical and clinical research and to bringing such advances to clinical practice [1–3]. Partnerships among pharmaceutical, device, and biotechnology industries, and physicians and scientists can encourage innovative approaches necessary to address complex health problems.…”